FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895957341> ?p ?o ?g. }

• W2895957341 endingPage "373" @default.
• W2895957341 startingPage "364" @default.
• W2895957341 abstract "Nivolumab, a fully human immunoglobulin G4 monoclonal anti-programmed death-1 antibody, has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma. The aim of this study was to characterize the pharmacokinetics (PK) of nivolumab in patients with classical Hodgkin lymphoma using a population approach and to assess the exposure-response (E-R) relationship for safety, thereby supporting the dose recommendation in patients with classical Hodgkin lymphoma. Nivolumab PK and the effect of covariates were consistent with that observed in solid tumors, except that baseline clearance of nivolumab was lower in patients with classical Hodgkin lymphoma by 28%. The E-R analysis for safety, characterized by a Cox proportional hazards model, indicated that the resulting increased nivolumab exposure (average concentration after the first dose) was not a significant predictor of the risk of grade ≥3 drug-related adverse events. Given the acceptable safety profile and observed benefit (65% objective response rate) with the nivolumab 3 mg/kg every 2 week dosing regimen for classical Hodgkin lymphoma, together with the flat E-R safety relationship, nivolumab demonstrated a favorable benefit-risk profile across the range of exposures of 3 mg/kg every 2 weeks in patients with classical Hodgkin lymphoma. Additional model-based simulation suggested that a flat dose of 240 mg every 2 weeks was predicted to produce similar exposures to that of 3 mg/kg every 2 weeks. Therefore, nivolumab 240 mg every 2 weeks is the recommended dosing regimen in the classical Hodgkin lymphoma population." @default.
• W2895957341 created "2018-10-26" @default.
• W2895957341 creator A5011152885 @default.
• W2895957341 creator A5060961800 @default.
• W2895957341 creator A5072754070 @default.
• W2895957341 creator A5080799931 @default.
• W2895957341 creator A5087099599 @default.
• W2895957341 creator A5089577043 @default.
• W2895957341 date "2018-10-19" @default.
• W2895957341 modified "2023-10-16" @default.
• W2895957341 title "Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma" @default.
• W2895957341 cites W1757383019 @default.
• W2895957341 cites W1974654770 @default.
• W2895957341 cites W1994993231 @default.
• W2895957341 cites W2042553471 @default.
• W2895957341 cites W2057499380 @default.
• W2895957341 cites W2089158135 @default.
• W2895957341 cites W2109485845 @default.
• W2895957341 cites W2125616358 @default.
• W2895957341 cites W2128294765 @default.
• W2895957341 cites W2130628097 @default.
• W2895957341 cites W2155256323 @default.
• W2895957341 cites W2169822687 @default.
• W2895957341 cites W2567068937 @default.
• W2895957341 cites W2587297698 @default.
• W2895957341 cites W2604963252 @default.
• W2895957341 cites W2620733650 @default.
• W2895957341 cites W2743004903 @default.
• W2895957341 cites W2754947201 @default.
• W2895957341 cites W297719929 @default.
• W2895957341 cites W4211016085 @default.
• W2895957341 cites W945635311 @default.
• W2895957341 doi "https://doi.org/10.1002/jcph.1324" @default.
• W2895957341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30339279" @default.
• W2895957341 hasPublicationYear "2018" @default.
• W2895957341 type Work @default.
• W2895957341 sameAs 2895957341 @default.
• W2895957341 citedByCount "9" @default.
• W2895957341 countsByYear W28959573412019 @default.
• W2895957341 countsByYear W28959573412020 @default.
• W2895957341 countsByYear W28959573412021 @default.
• W2895957341 countsByYear W28959573412022 @default.
• W2895957341 crossrefType "journal-article" @default.
• W2895957341 hasAuthorship W2895957341A5011152885 @default.
• W2895957341 hasAuthorship W2895957341A5060961800 @default.
• W2895957341 hasAuthorship W2895957341A5072754070 @default.
• W2895957341 hasAuthorship W2895957341A5080799931 @default.
• W2895957341 hasAuthorship W2895957341A5087099599 @default.
• W2895957341 hasAuthorship W2895957341A5089577043 @default.
• W2895957341 hasConcept C112705442 @default.
• W2895957341 hasConcept C121608353 @default.
• W2895957341 hasConcept C126322002 @default.
• W2895957341 hasConcept C143998085 @default.
• W2895957341 hasConcept C197934379 @default.
• W2895957341 hasConcept C2777288759 @default.
• W2895957341 hasConcept C2777701055 @default.
• W2895957341 hasConcept C2779338263 @default.
• W2895957341 hasConcept C2780030458 @default.
• W2895957341 hasConcept C2781413609 @default.
• W2895957341 hasConcept C2908647359 @default.
• W2895957341 hasConcept C2910914307 @default.
• W2895957341 hasConcept C2992779791 @default.
• W2895957341 hasConcept C71924100 @default.
• W2895957341 hasConcept C98274493 @default.
• W2895957341 hasConcept C99454951 @default.
• W2895957341 hasConceptScore W2895957341C112705442 @default.
• W2895957341 hasConceptScore W2895957341C121608353 @default.
• W2895957341 hasConceptScore W2895957341C126322002 @default.
• W2895957341 hasConceptScore W2895957341C143998085 @default.
• W2895957341 hasConceptScore W2895957341C197934379 @default.
• W2895957341 hasConceptScore W2895957341C2777288759 @default.
• W2895957341 hasConceptScore W2895957341C2777701055 @default.
• W2895957341 hasConceptScore W2895957341C2779338263 @default.
• W2895957341 hasConceptScore W2895957341C2780030458 @default.
• W2895957341 hasConceptScore W2895957341C2781413609 @default.
• W2895957341 hasConceptScore W2895957341C2908647359 @default.
• W2895957341 hasConceptScore W2895957341C2910914307 @default.
• W2895957341 hasConceptScore W2895957341C2992779791 @default.
• W2895957341 hasConceptScore W2895957341C71924100 @default.
• W2895957341 hasConceptScore W2895957341C98274493 @default.
• W2895957341 hasConceptScore W2895957341C99454951 @default.
• W2895957341 hasFunder F4320307115 @default.
• W2895957341 hasIssue "3" @default.
• W2895957341 hasLocation W28959573411 @default.
• W2895957341 hasLocation W28959573412 @default.
• W2895957341 hasOpenAccess W2895957341 @default.
• W2895957341 hasPrimaryLocation W28959573411 @default.
• W2895957341 hasRelatedWork W1499958231 @default.
• W2895957341 hasRelatedWork W1976159180 @default.
• W2895957341 hasRelatedWork W2004325424 @default.
• W2895957341 hasRelatedWork W2051764329 @default.
• W2895957341 hasRelatedWork W2088178090 @default.
• W2895957341 hasRelatedWork W2169927017 @default.
• W2895957341 hasRelatedWork W2793520024 @default.
• W2895957341 hasRelatedWork W3021369409 @default.
• W2895957341 hasRelatedWork W4240491315 @default.
• W2895957341 hasRelatedWork W4280556106 @default.
• W2895957341 hasVolume "59" @default.

• next